These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 31941015)

  • 61. Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits.
    Emhmed Ali S; Nguyen MH
    Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33557355
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
    Lim S; Oh TJ; Koh KK
    Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia.
    Biolo G; Cederholm T; Muscaritoli M
    Clin Nutr; 2014 Oct; 33(5):737-48. PubMed ID: 24785098
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictors of metabolic risk in childhood obesity.
    Morandi A; Maffeis C
    Horm Res Paediatr; 2014; 82(1):3-11. PubMed ID: 24923289
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Insulin resistance in obesity: an overview of fundamental alterations.
    Barazzoni R; Gortan Cappellari G; Ragni M; Nisoli E
    Eat Weight Disord; 2018 Apr; 23(2):149-157. PubMed ID: 29397563
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance.
    Noland RC; Woodlief TL; Whitfield BR; Manning SM; Evans JR; Dudek RW; Lust RM; Cortright RN
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E986-E1001. PubMed ID: 17638705
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor.
    Lefranc C; Friederich-Persson M; Palacios-Ramirez R; Nguyen Dinh Cat A
    J Endocrinol; 2018 Sep; 238(3):R143-R159. PubMed ID: 29875164
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epigenetic contribution to obesity.
    Ouni M; Schürmann A
    Mamm Genome; 2020 Jun; 31(5-6):134-145. PubMed ID: 32279091
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity.
    Ma J; Hwang SJ; McMahon GM; Curhan GC; Mclean RR; Murabito JM; Fox CS
    Obesity (Silver Spring); 2016 Feb; 24(2):526-34. PubMed ID: 26813531
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inflammatory mechanisms linking obesity and metabolic disease.
    Saltiel AR; Olefsky JM
    J Clin Invest; 2017 Jan; 127(1):1-4. PubMed ID: 28045402
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.
    Cabrera D; Ruiz A; Cabello-Verrugio C; Brandan E; Estrada L; Pizarro M; Solis N; Torres J; Barrera F; Arrese M
    Dig Dis Sci; 2016 Nov; 61(11):3190-3198. PubMed ID: 27572941
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions.
    Li L; Yang X
    Oxid Med Cell Longev; 2018; 2018():7580707. PubMed ID: 29849912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Obesity and inflammation.
    Karczewski J; Śledzińska E; Baturo A; Jończyk I; Maleszko A; Samborski P; Begier-Krasińska B; Dobrowolska A
    Eur Cytokine Netw; 2018 Sep; 29(3):83-94. PubMed ID: 30547890
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
    Finck BN
    Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
    Chávez-Talavera O; Haas J; Grzych G; Tailleux A; Staels B
    Curr Opin Lipidol; 2019 Jun; 30(3):244-254. PubMed ID: 30893108
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sarcopenia.
    Tournadre A; Vial G; Capel F; Soubrier M; Boirie Y
    Joint Bone Spine; 2019 May; 86(3):309-314. PubMed ID: 30098424
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Insulin resistance and the endothelium.
    Quiñones MJ; Nicholas SB; Lyon CJ
    Curr Diab Rep; 2005 Aug; 5(4):246-53. PubMed ID: 16033673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise.
    Minniti G; Pescinini-Salzedas LM; Minniti GADS; Laurindo LF; Barbalho SM; Vargas Sinatora R; Sloan LA; Haber RSA; Araújo AC; Quesada K; Haber JFDS; Bechara MD; Sloan KP
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362238
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Redox regulation of insulin sensitivity due to enhanced fatty acid utilization in the mitochondria.
    Rindler PM; Crewe CL; Fernandes J; Kinter M; Szweda LI
    Am J Physiol Heart Circ Physiol; 2013 Sep; 305(5):H634-43. PubMed ID: 23792672
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
    Veiga FMS; Graus-Nunes F; Rachid TL; Barreto AB; Mandarim-de-Lacerda CA; Souza-Mello V
    Biochimie; 2017 Sep; 140():106-116. PubMed ID: 28711683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.